As Wyeth Pharmaceuticals defends itself against antitrust claims in San Francisco Superior Court, its legal battles may lead to a new rule for opting out of class actions.

A class action and an unfair competition suit, which have been coordinated before a San Francisco judge for more than a year, both accuse Wyeth of squelching competition to its drug Premarin, which treats hot flashes and other symptoms of menopause.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]